Phase 1 Study of dmLT ID Vaccination in Healthy Adults

Condition:   Gastroenteritis Escherichia Coli
Interventions:   Other: Placebo;   Biological: Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral entertoxigenic Escherichia coli (ETEC) Vaccine
Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting - verified January 4, 2017